Literature DB >> 30363537

Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease.

Olivier Rascol1,2.   

Abstract

Entities:  

Year:  2016        PMID： 30363537      PMCID： PMC6178700          DOI： 10.1002/mdc3.12389

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  18 in total

Review 1.  New treatments for levodopa-induced motor complications.

Authors:  Olivier Rascol; Santiago Perez-Lloret; Joaquim J Ferreira
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

2.  Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.

Authors:  Leo Verhagen Metman; Natividad Stover; Cuiping Chen; Verne E Cowles; Michael Sweeney
Journal:  Mov Disord       Date:  2015-04-02       Impact factor: 10.338

Review 3.  Apomorphine hydrochloride for the treatment of Parkinson's disease.

Authors:  Elisa Unti; Roberto Ceravolo; Ubaldo Bonuccelli
Journal:  Expert Rev Neurother       Date:  2015-06-02       Impact factor: 4.618

4.  Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?

Authors:  Alison J Yarnall; Tammaryn Lashley; Helen Ling; Andrew J Lees; Shirley Y Coleman; Sean S O'Sullivan; Yaroslau Compta; Tamas Revesz; David J Burn
Journal:  Mov Disord       Date:  2015-10-13       Impact factor: 10.338

5.  Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.

Authors:  Miho Murata; Kazuko Hasegawa; Ichiro Kanazawa; Junichi Fukasaka; Kenji Kochi; Rieko Shimazu
Journal:  Mov Disord       Date:  2015-06-12       Impact factor: 10.338

Review 6.  Clinical spectrum of levodopa-induced complications.

Authors:  Camila Catherine Aquino; Susan H Fox
Journal:  Mov Disord       Date:  2014-12-08       Impact factor: 10.338

7.  Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.

Authors:  Stewart A Factor; Kenneth Wolski; Daniel M Togasaki; Susan Huyck; Marc Cantillon; T W Ho; Robert A Hauser; Emmanuelle Pourcher
Journal:  Mov Disord       Date:  2013-04-15       Impact factor: 10.338

Review 8.  The scientific and clinical basis for the treatment of Parkinson disease (2009).

Authors:  C Warren Olanow; Matthew B Stern; Kapil Sethi
Journal:  Neurology       Date:  2009-05-26       Impact factor: 9.910

9.  Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

Authors:  Stuart Isaacson; Mark Lew; William Ondo; Jean Hubble; Thomas Clinch; Fernando Pagan
Journal:  Mov Disord Clin Pract       Date:  2016-05-25

10.  Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

Authors:  Yoshikuni Mizuno; Tomoyoshi Kondo
Journal:  Mov Disord       Date:  2013-03-11       Impact factor: 10.338
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.